"Zentalis reported significant progress in the development of azenosertib in 2024 and made important advancements this year. We plan to maintain strong execution on the late-stage development of ...

WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader, NKT3964, by completing the dosing of the first patient cohort in a ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...

NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for treating adults with advanced or metastatic solid tumours. The dose-escalation ...

demonstrated that targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia. Findings from Olle Sangfelt's group at the Department of ...

The important paper provides compelling evidence that the gene hkb controls the development of the salivary gland of Drosophila by controlling a cell cycle and cell death. The work extends and ...

disease severity and Cyclin E1 expression. These data indicate that PRMT5 promotes G1/S cell cycle progression and suggest that this effect influences disease severity and/or progression in the animal ...

We found that the expression levels of CDK2, Cyclin E1 (CCNE1) and Cyclin E2 (CCNE2) were decreased in BD-treated cells in a dose- and time- dependent manner (Figures 2C,D). These results suggest that ...

produced higher levels of cyclin D (a protein required for cell cycle progression) and showed higher levels of pH3 than those on adhesion-poor soft gels (Figure 2E and F). Long glycopolymer-treated ...